Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Teva
Medtronic
McKesson
Healthtrust
McKinsey
UBS
Farmers Insurance
Harvard Business School
Accenture

Generated: February 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,096,742

« Back to Dashboard

Which drugs does patent 6,096,742 protect, and when does it expire?

Patent 6,096,742 protects EMEND and is included in two NDAs.

This patent has forty-five patent family members in thirty-four countries.
Summary for Patent: 6,096,742
Title: Polymorphic form of a tachykinin receptor antagonist
Abstract:This invention is concerned with a novel polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)-ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine which is a tachykinin receptor antagonist useful in the treatment or prevention of disorders of the central nervous system, inflammatory diseases, pain or migraine, asthma, and emesis. The instant polymorphic form has advantages over the other known forms of 2-(R)-(1-(R)-(3,5-bis(trifluoro-methyl)-phenyl)ethoxy)-3-(S)-(4-fluoro)phe nyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations.
Inventor(s): Crocker; Louis (Belle Mead, NJ), McCauley; James (Belle Mead, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/212,511
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,096,742

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OR PREVENTION OF EMESIS ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OR PREVENTION OF EMESIS ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,096,742

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,229,010 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
6,432,953 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
6,583,142 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,096,742

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 577887 ➤ Try a Free Trial
Turkey 9903299 ➤ Try a Free Trial
Slovakia 285644 ➤ Try a Free Trial
Slovakia 187299 ➤ Try a Free Trial
Saudi Arabia 1164 ➤ Try a Free Trial
Serbia 49980 ➤ Try a Free Trial
Poland 191496 ➤ Try a Free Trial
Poland 337579 ➤ Try a Free Trial
Peru 86499 ➤ Try a Free Trial
New Zealand 501589 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Healthtrust
Queensland Health
Johnson and Johnson
Cipla
McKesson
Deloitte
US Army
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot